



TO: Jesse Ellis O'Brien
Senior Policy Analyst
Oregon Department of Consumer and Business Services Division of Financial Regulation

FR: Catie Theisen, Political Organizer
Oregon Nurses Association
Jan. 24, 2019

Mr. O'Brien,

The Oregon Nurses Association appreciates the opportunity to provide our support for the proposed rules for the Prescription Drug Price Transparency Act (HB 4005, 2018).

The Oregon Nurses Association is proud to represent over 15,000 Oregon nurses that make up the largest segment of Oregon's health care work force. ONA members work in nearly every health care setting imaginable, from large hospitals to small local clinics, from corrections to school based health centers, and community-based public health. As such, ONA is dedicated to finding solutions to address prescription drug cost transparency to improve the delivery of successful, timely, and affordable patient care.

We'd like to emphasize a few key provisions that are in the draft that we see as critical to the intent and effective implementation of HB 4005. This includes maintaining the current definition in the draft of "Net Yearly Increase", a robust review process that analyzes protected information such as manufacturer "trade secrets" weighted against the public interest, and reporting requirements for manufacturer sponsored *and* independently operated patient assistant programs to ensure true transparency.

ONA believes that transparency is an essential component of lowering what manufacturers charge for medications. Oregon nurses are committed to ensuring HB 4005 is implemented as intended by exposing prescription drug pricing factors to public scrutiny. We hope that you support these proposed rules to effect meaningful change for our patients across Oregon.

Sincerely,

Catie Theisen
Oregon Nurses Association